Devgen acquires Elegene assets

Published: 21-Aug-2002


Devgen, a privately held functional genomics and drug discovery company based in Ghent, Belgium, has acquired proprietary assets from Munich-based Elegene, including image acquisition technology and a library of disease models in CNS for pain, Parkinson's and Alzheimer's disease. These proprietary assets fit Devgen's disease focus, and broaden its offerings to pharmaceutical companies.

Devgen's technology platform includes the model organism Caenorhabditis elegans, which has a high conservation of biological pathways with humans. According to the company it is an excellent tool to prioritise and select therapeutically relevant targets. Elegene was focused on the use of the model organism C. elegans as a tool for target discovery and validation in CNS related diseases.

'The acquisition of Elegene's assets enhances Devgen's position as a leader in the exploitation of the model organism C. elegans,' said Dr Thierry Bogaert, ceo of Devgen.

You may also like